Groupe d'Etude en Oncologie du Quebec

Titre	Biomarker Verification in Pediatric Chronic Graft-Versus-Host Disease: Applied Biomarkers to Minimize Long Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) / Pediatric Transplantation & Cellular Therapy Consortium (PTCTC)
Protocole ID	ABLE 2.0 /? PTCTC GVH 1901
ClinicalTrials.gov ID	NCT04372524
Type(s) de cancer	Pédiatrique divers
Phase	Autres
Institution	CENTRE UNIVERSITAIRE DE SANTE MCGILL HOPITAL DE MONTREAL POUR ENFANTS 1001 boul. Décarie , Montréal, QC, H4A 3J1
Ville	Montréal
Investigateur(trice) principal(e)	Dr David Mitchell
Coordonnateur(trice)	Samira Mezziani 514-412-4400 poste 22930
Statut	Actif en recrutement
Critètes d'éligibilité	Any indication for allogeneic hematopoietic stem cell transplant (malignant or non-malignant) Age 0 - 24.99 years at the time of transplant (on day 0) Any conditioning regimen (including myeloablative or reduced-toxicity/reduced-intensity) Any graft source (bone marrow, peripheral blood, cord blood) Any graft-versus-host disease prophylaxis strategy, including serotherapy such as ATG or alemtuzumab Haploidentical transplants, including post-transplant cyclophosphamide and alpha-beta TCR depletion, are allowed
Critètes d'exclusion	Second or greater allogeneic transplant Weight 7 kg or less Pure CD34+ selected haploidentical stem cell transplant (not including CD34 enrichment used in alpha-beta TCR depleted haploidentical transplants, which is allowed) Inability of a center to follow a patient for the development of late-acute and chronic GVHD until 1-year post-transplant (referral sites who transplant patients from outside institutions should not enroll participants if sending back to the referring site early, such that long-term follow up, blood, and data collection cannot be assured).

Groupe d'étude en oncologie du Québec